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The adenomatous polyposis coli (APC) tumor sup-
pressor is mutated in the vast majority of human
colorectal cancers (CRC) and leads to deregulated
Wnt signaling. To determine whether Apc disruption
is required for tumor maintenance, we developed
a mouse model of CRC whereby Apc can be condi-
tionally suppressed using a doxycycline-regulated
shRNA. Apc suppression produces adenomas in
both the small intestine and colon that, in the pres-
ence of Kras and p53 mutations, can progress to
invasive carcinoma. In established tumors, Apc res-
toration drives rapid and widespread tumor-cell
differentiation and sustained regression without re-
lapse. Tumor regression is accompanied by the re-
establishment of normal crypt-villus homeostasis,
such that once aberrantly proliferating cells reac-
quire self-renewal and multi-lineage differentiation
capability. Our study reveals that CRC cells can
revert to functioning normal cells given appropriate
signals and provide compelling in vivo validation of
the Wnt pathway as a therapeutic target for treat-
ment of CRC.
INTRODUCTION
Colorectal cancer (CRC) is the second leading cause of cancer-
related death in developed countries, and almost half of the
population will develop at least one benign intestinal tumor dur-
ing their lifetime (Jemal et al., 2011). Treatment regimes for
advanced CRC involve combination chemotherapies that are
toxic and largely ineffective, yet have remained the backbone
of therapy over the last decade. Molecularly, the vast majority
(80%–90%) of colorectal tumors contain inactivating muta-
tions in the adenomatous polyposis coli (APC) tumor suppressor(Brannon et al., 2014), and individuals with specific germline mu-
tations in APC (familial adenomatous polyposis or FAP) invari-
ably develop colon cancer before the age of 35. Collectively,
APCmutant CRC accounts for more than 600,000 deaths annu-
ally worldwide, a number greater than KRAS mutant lung or
pancreas cancer. Hence, strategies to exploit APC alterations
in CRC have broad clinical potential.
APC regulates a number of cellular functions, including
mitosis, migration, and the maintenance of genome stability
(Nelson and Na¨thke, 2013). Most importantly, APC, along with
AXIN1 and GSK3b, is part of a multi-protein complex that con-
trols output of the Wnt signaling pathway by regulating the
sub-cellular localization and stability of CTNNB1 (b-catenin), a
key transcriptional regulator that drives Wnt signaling output.
APC inactivation is considered the initiating event in most
CRCs, and Apc loss is sufficient to induce benign and dysplastic
adenomas in the small and large mouse intestine (Cheung et al.,
2010; Su et al., 1992). ApcMin (Multiple Intestinal Neoplasia) mice
carry a single mutant Apc allele and develop 50–100 benign ad-
enomas in the small intestine by 4–6 months of age, invariably
associated with loss of the remaining wild-type gene (Su et al.,
1992). Conditional Apc truncation drives a similar neoplastic
phenotype, associated with hyperproliferation, reduced multi-
lineage differentiation, disrupted tissue structure, and an expan-
sion of intestinal stem cells outside the crypt domain (Barker
et al., 2009; Sansom et al., 2004).
Besides APC disruption, CRCs show a high incidence of mu-
tations in KRAS (45%) and TP53 (54%) that cooperate to drive
tumor progression (Cancer Genome Atlas Network, 2012). Addi-
tionally, recent large-scale sequencing efforts have cataloged
additional genetic changes that likely influence disease progres-
sion (Cancer Genome Atlas Network, 2012). Still, little is known
about which, if any, of these alterations are required for mainte-
nance of established disease and continued malignant progres-
sion. Indeed, it remains unclear whether APC disruption, the
predominant CRC-associated event, is required formaintenance
of CRC and thuswhether hyperactivatedWnt signaling is a viable
therapeutic target.Cell 161, 1539–1552, June 18, 2015 ª2015 Elsevier Inc. 1539
To address this question, we generated shRNA transgenic
mice that enable conditional and reversible control of Apc
expression by TRE-regulated, GFP-linked short-hairpin RNAs
(TG-shRNAs) (Dow et al., 2012; Premsrirut et al., 2011). In mice
that also express a reverse tet-transactivator (rtTA), doxycycline
(dox) administration drives GFP expression and Apc silencing,
and subsequent dox withdrawal results in restoration of endog-
enous Apc expression. Our work demonstrates a crucial role for
Apc loss in CRC maintenance and reveals an unexpected ability
of Apc to re-establish control of crypt homeostasis in animals
with hyperproliferative polyps or cancer. Collectively, our results
validate the APC/WNT pathway is an attractive target for the
treatment of CRC.
RESULTS
Potent Apc Silencing Blocks Differentiation and Drives
Hyperproliferation in the Intestine
Acute genetic disruption of Apc in the intestine drives hyperpro-
liferation and expansion of undifferentiated progenitor cells (San-
som et al., 2004). This results in the disruption of the crypt-villus
axis, whereby stem and progenitor cells, normally restricted to
the crypt base, expand and fail to differentiate as they move up
the villus (Sansom et al., 2004). To assess how shRNA-mediated
Apc suppression affects crypt-villus homeostasis, we examined
Wnt pathway activation in the intestinal epithelium inmultipleApc
shRNA strains (TG-Apc.3374 and TG-Apc.9365) (Premsrirut
et al., 2011). We observed that only the most potent suppression
of Apc (TG-Apc.3374) causedan increase in non-phosphorylated
b-catenin in the intestine (Figure S1A). This response was further
amplified with a CAGs-rtTA3 transgene, driving greater Apc
knockdown and more than 20-fold transcriptional induction of
the canonical Wnt target Axin2 (Figures S1A and S1B).
To examine the intestinal response to Apc silencing, we
treated TG-Apc.3374 (hereafter, shApc) animals with dox and
monitored their weight as a surrogate measure of intestinal func-
tion. After 6 days of dox treatment shApc animals began to show
signs of weight loss relative to neutral TG-shRen.713 (shRen)
controls (Zuber et al., 2011), and by day 10, shApc mice were
lethargic and moribund (Figure 1A). Depletion of Apc caused a
marked expansion of alkaline phosphatase (AP) and keratin 20
(Krt20) negative progenitors and hyperproliferation throughout
the crypt-villus axis (Figure 1B). The block in differentiation and
expansion of stem and progenitor cells was further confirmed
by the identification of lysozyme-positive Paneth cells and Lgr5
and Olfm4-positive stem cells outside their normal position at
the base of the crypt (Figure 1B). Apc silencing induced a pro-
gressive increase in the expression of canonical Wnt targets,
including Axin2 and cMyc, as well as markers of intestinal stem
cells Lgr5 and Ascl2 (Figures 1C and 1D). Importantly, a second
transgenic strain harboring an independent and potent Apc
shRNA (TG-Apc.2235E) produced identical phenotypes (Fig-
ure 1A, Figure S1C).
These data demonstrate that shRNA-driven Apc silencing can
recapitulate the conditional knockout phenotype (Sansom et al.,
2004). However, in contrast to genetic deletions, shRNAs sup-
press gene function in trans, and, as such, the endogenous pro-
tein can be restored simply by eliminating shRNA expression. To1540 Cell 161, 1539–1552, June 18, 2015 ª2015 Elsevier Inc.assess whether Apc restoration could rescue the intestinal
dysfunction, we treated shApc mice for 10 days and then with-
drew dox from the diet. Apc restoration induced a rapid and dra-
matic phenotypic response, and by 8 days themice recovered to
their original weight (Figure 1A). Within 2 days of dox withdrawal,
GFP-shRNA transcription from the TRE promoter was reduced
more than 100-fold and by 4 days had returned almost to base-
line levels (Figure 1C). Remarkably, 4 days of dox withdrawal
was sufficient to restore crypt-villus homeostasis as evidenced
by basal localization of proliferative stem and progenitor cells
and lysozyme+ Paneth cells, while differentiated markers (AP,
Krt20) were strongly expressed throughout the villus (Figure 1B).
Accordingly, a decrease in levels of Wnt-responsive mRNAs, as
well as Myc protein, were apparent as early as 2 days after dox
withdrawal and returned to baseline by 4 days (Figures 1C and
1D). Together these data show that acute Apc suppression reca-
pitulates the phenotypes of Apc deletion and, importantly, that
restoration of endogenous Apc expression can recover normal
intestinal function.
AMosaicModel of shRNA-Driven Tumor Development in
the Small and Large Intestine
The above results are striking and highlight the utility of inducible
shRNA transgenic mice to study the reversibility of loss of func-
tion phenotypes. However, these models are not ideal for study-
ing cancer, as tissue-wide Apc suppression produces lethality
well before mice develop intestinal tumors. Moreover, tumori-
genesis in humans initiates from individual mutated cells
surrounded by otherwise normal tissue. To address this, we
modeled mosaic Apc loss by combining a stem cell restricted
4-hydroxytamoxifen (4OHT)-inducible CreER strain (Lgr5-GFP-
IRES-CreER, hereafter Lgr5-CreER) (Barker et al., 2007) with a
Cre-dependent R26-CAGs-LSL-rtTA3 (LSL-rtTA3) strain that
we recently generated (Dow et al., 2014). In these mice, a
single treatment with 4OHT initiates LoxP-recombination in
stem cells of the small and large intestine, inducing long-lived,
rtTA3 expression in a small percentage of individual crypts and
villi (Figures S2A and S2B). In LSL-rtTA3 / Lgr5-CreER / TG-
Ren.713 (shRen/Lgr5) control mice treated with 4OHT and dox
we observed GFP induction in individual crypts and villi
throughout the length of the small intestine and colon for up to
40 weeks (Figure S2C, data not shown). Of note, the shRNA
linked GFP reporter is significantly more abundant than GFP ex-
pressed from the Lgr5-GFP-IRES-CreER knockin allele and can
be used as a surrogate marker of shRNA expression and Apc
knockdown.
Next, we generated LSL-rtTA3 / Lgr5-CreER / shApc (shApc/
Lgr5) mice and monitored tumor development longitudinally by
small animal colonoscopy. Four-to-six weeks following 4OHT/
dox treatment, we noted the development of macroscopic
polyps in the small intestine and colon (Figure 2A, Figure S3).
By 12–16 weeks, shApc/Lgr5 mice developed large colonic
polyps that appeared histologically as well-differentiated tubular
adenomas. As is characteristic of tumors initiated bymutations in
Apc, polyps arising in shApc/Lgr5 animals showed a massive in-
crease in proliferation,markedbyBrdU incorporation (Figure 2B).
These lesions also carried reduced numbers of Krt20+ entero-
cytes and Alcian blue+ goblet cells and showed a significant
Figure 1. Acute Depletion of Apc in the Mouse
(A) Animal weight during dox treatment and following dox withdrawal at 10 days, normalized to day 0 within each cohort. Lines represent TG-Ren.713 (black),
TG-Apc.3374 (green), and TG-Apc.2235E (blue) mice. Error bars represent SD (nR 6).
(B) Immunohistochemical (H&E, alkaline phosphatase and lysozyme), immunofluorescent (Ki67 and keratin 20) stains and in situ hybridizations (Lgr5 and Olfm4)
from TG-Ren.713 (control) and TG-Apc.3374 intestine following dox treatment for 10 days (left two panels) and withdrawn from dox for 4 days (right panel).
(C) qRT-PCR analysis of gene expression in intestinal villi following dox treatment and withdrawal for shApc mice as indicated. Markers of transgene induction
(GFP),Wnt activation (Axin2, Myc), and stem cells (Lgr5, Ascl2) are shown for each time point. Gene expression in day 10-treated shRen is indicated to the right on
each plot. Plots represent the mean ± SEM (nR 3).
(D) Western blot of whole cell lysates from intestinal villi following dox treatment and withdrawal at time points indicated, for shRen and shApc mice, probed for
Apc, GFP, cMyc, and b-Actin, as indicated.
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Figure 2. Apc Knockdown Drives the Development of Colonic Polyps
(A) Colon endoscopic images from LSL-rtTA3 / shRen / Lgr5-CreER (shRen) or LSL-rtTA3 / shApc/Lgr5-CreER (shApc) mice following dox treatment for times
indicated, showing gradual polyp development in shApc/Lgr5 animals.
(B) Immunohistochemical (H&E, Alcian blue) and immunofluorescent (GFP/BrdU and Krt20) stains and in situ hybridization (Lgr5) from shRen/Lgr5 and shApc/
Lgr5 colons following dox treatment for 10 weeks.
(C) Hematocrit in peripheral blood of shRen/Lgr5 and shApc/Lgr5 mice over time following 4OHT and dox treatment. Plots represent the mean ± SEM (nR6).
(D) Kaplan-Meier plot showing survival of dox-treated ApcMin/+ (red line), Apcflox/flox / Lgr5 (blue line), shRen/Lgr5 (black line), and shApc/Lgr5 (green line).
Lgr5-CreER containing mice were treated with 4OHT at 5–6 weeks of age and all animals (including ApcMin/+) were treated continually with doxycycline from this
time onward.
(legend continued on next page)
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increase in Lgr5+ stem cells outside of their normal position at the
crypt base (Figure 2B, FigureS3). Together, thesedata highlight a
block in the production of differentiated cell types and an expan-
sion of the stem and progenitor compartment.
In line with previous observations in ApcMin animals (Moser
et al., 1990), shApc/Lgr5 mice treated with 4OHT displayed a
progressive decrease in hematocrit, associated with blood loss
following polyp development (Figure 2C), and a median survival
of 115 days (Figure 2D). However, in contrast to Apcfl/fl/Lgr5 (and
ApcMin) animals that developed disease almost exclusively in the
small intestine, concentrated in the distal jejunum and ileum
(Figure 2E), tumors in shApc/Lgr5 mice arose in the colon and
duodenum/proximal jejunum (Figures 2E and 2F), which more
closely reflects the anatomy of disease presentation in FAP
patients (Sarre et al., 1987). This regional difference in tumor dis-
tribution was not due to the restricted activation of Cre, or doxy-
cycline treatment, as we observed Cre recombination (GFP
induction) throughout the small intestine and colon (Figure S2C),
and both ApcMin and Apcfl/fl/Lgr5-CreERmice were treated with
dox from 5–6 weeks of age. Regardless of the precise mecha-
nism, the appearance of colorectal disease enabled longitudinal
studies of disease progression and/or regression in live mice us-
ing small animal endoscopy.
To examine the molecular characteristics of colonic ade-
nomas formed in shApc/Lgr5 mice, we performed gene expres-
sion analysis by RNAseq and identified 3,225 (1,339 up, 1,886
down) genes that were significantly deregulated (2-fold or
greater) relative to shRen/Lgr5 control mucosa. This expression
signature was enriched for both up and downregulated tran-
scripts identified in human colorectal cancers (Stages I-IV,
FDR < .001) (Figure 2G, Figure S2D) (Ongen et al., 2014) as
well as human colon adenomas (FDR < .001) (Figure S2D) (Sa-
bates-Bellver et al., 2007). shApc/Lgr5 tumors also contained
an overrepresentation of transcripts found in purified Lgr5+
stem cells and enterocyte progenitors (FDR < .001) and an un-
derrepresentation of genes exclusively expressed in secretory
progenitors or enterocytes (Figure S2D and Table S1) (Kim
et al., 2014). Further, shApc/Lgr5 colon tumors showed a
decrease in Krt20 (Figure 2B) andSlc26a3 expression (Figure 2G,
bottom), which together, define a two-gene classifier that is
associated with poor prognosis in human CRC (Dalerba et al.,
2011). Thus, the gene expression profile of shApc/Lgr5 tumors
is consistent with our histological analyses and indicates that
Apc suppression impairs differentiation and drives the expansion
of progenitor cells. In all, the histological, anatomical, andmolec-
ular characteristics of colon adenomas formed in shApc/Lgr5
mice suggest they accurately reflect the early stages of human
colorectal cancer.(E) Quantification of tumor burden from H&E stained paraffin embedded section
percentage of total tumor burden for each of five intestinal regions representing th
represent the mean ± SEM (nR 5).
(F) Dot plot showing number of macroscopic polyps counted in whole mount colo
bars are the SEM (nR 8).
(G) Heatmap representing the top 50 up (red) and downregulated (blue) transcrip
abundance (log2 fold change) for each gene is also shown for shApc/Kras tumors
et al., 2014). Genes listed to the right are those among the top 50 deregulated in
validated by qRT-PCR.Apc Restoration Promotes Disease Regression in the
Small and Large Intestine
We next asked whether sustained Apc loss was essential for
disease maintenance by restoring endogenous Apc protein
expression in established polyps of shApc/Lgr5mice. The tumor
response to dox withdrawal was striking: in the colon, longitudi-
nal endoscopic imaging of dox-withdrawn animals showed rapid
regression of polyps over many weeks (Figure 3A, Figure S3A).
Small intestinal polyps regressed evenmore rapidly, and indeed,
no macroscopic polyps were visible in the small intestine after
two weeks of Apc restoration (Figure S3C). In some cases, we
noted the persistence of small polyp-like masses visible in the
colon for weeks following dox withdrawal (Figure S3A, arrows).
While abnormal in structure, these masses were composed
of histologically normal, differentiated epithelium (Figure S3A,
right), perhaps retained due to irreversible changes in tissue
structure or fibrosis during tumor growth.
As expected, the marked response to Apc reactivation was
associated with a corresponding decrease in Wnt target gene
expression (Figure 3D). However, in contrast to studies
showing forced overexpression of APC in tumor cells can
promote apoptosis (Morin et al., 1996), endogenous Apc pro-
duced no increase in apoptotic cell death as measured by his-
tology and lack of cleaved-Caspase 3 staining (Figure 3C, Fig-
ure S3C). Instead, Apc restoration was associated with rapid
cell-cycle arrest and massive differentiation. Specifically,
within 4 days following dox withdrawal, almost all tumor cells
had ceased proliferation (Figure 3B, Figure S3B), showed a
dramatic increase in Krt20 expression, and a decrease in
Lgr5+ stem cells within the polyp (Figure 3C, Figure S3C).
The tumor suppressive effect of Apc was potent, and indeed,
we have never observed relapsed disease in the small intestine
or colon in mice monitored up to 6 months following Apc resto-
ration (n = 13, Figure 3E).
Apc Re-expression Restores Homeostasis in the
Intestinal Crypt
The rapid differentiation response of cells within adenomas
prompted us to explore if any Apc-restored cells remained at
the site of the regressed adenoma or if they were eliminated as
differentiated epithelial tissue. In our model, bright GFP expres-
sion marks Cre-recombined cells that express a dox-dependent
shRNA, however, following dox withdrawal, GFP expression is
lost. To identify any remaining tumor cells 2 weeks following
Apc restoration, we pulsed mice with dox for 2 days (Figure 4A).
Importantly, 2 days is sufficient time to induce GFP expres-
sion and thus ‘‘lineage trace’’ Cre-recombined cells, but not
long enough to produce a hyperproliferative response to Apcs of Apcflox/flox / Lgr5 and shApc/Lgr5 mice. Tumor area was calculated as a
e duodenum, proximal and distal jejunum, ileum, and colon, as indicated. Bars
n tissue in ApcMin/+, Apcflox/flox / Lgr5, and shApc/Lgr5mice at necropsy. Error
ts in shApc colonic adenomas relative to shRen mucosa (OFF Dox). Transcript
, shRenmucosa (ON Dox) and in human Stage I-IV colorectal cancers (Ongen
both the mouse shApc and Human CRC datasets, and those genes in bold are
Cell 161, 1539–1552, June 18, 2015 ª2015 Elsevier Inc. 1543
Figure 3. Apc Restoration Drives Adenoma
Regression
(A) Longitudinal colonoscopic images of a dox-
treated shApc/Lgr5mouse at 8 and 15 weeks, and
following 2, 8, and 15 weeks of dox withdrawal.
(B) Immunofluorescent stains for BrdU (green) in
colonic adenomas either ON Dox or 1, 2, or 4 days
following dox withdrawal, showing progressive
decrease in cells incorporating nucleotide.
(C) Immunohistochemical (H&E), immunofluores-
cent (keratin 20 and Cleaved Caspase 3) stains
and in situ hybridization (Lgr5) from shRen/Lgr5
and shApc/Lgr5 colon/adenomas following dox
treatment for 12–15 weeks (left two panels) and
withdrawal from dox for 4 days and 20weeks (right
two panels).
(D) qRT-PCR analysis of Wnt target genes (Axin2,
Myc) and stem cell markers (Lgr5, Ascl2) in iso-
lated colonic adenomas (shApc/Lgr5) and normal
mucosa (shRen/Lgr5) 15 weeks on dox and 4 days
following dox withdrawal, as indicated. Values are
normalized to shRen (on dox) for each target. Bars
represent the mean ± SEM (nR 4).
(E) Kaplan-Meier plot showing survival of dox-
treated shApc/Lgr5 mice (dotted green line,
also represented in Figure 2D) and shApc/Lgr5
mice removed from dox treatment between 12–
16 weeks (blue line).silencing (Figure 4B, ‘‘shApc - naive label’’). GFP re-labeling in
control (shRen/Lgr5) mice revealed entirely GFP-positive crypts,
indicating the presence of long-lived, Cre-recombined stem cells
that contribute continually to the normal mucosa (Figure 4B,
‘‘shRen re-label’’). In regressing adenomas, we noted similar
GFP ‘‘ribbons’’ extending from the crypt base to the outer differ-
entiated epithelium (Figure 4B, ‘‘shApc re-label’’). GFP-positive
regions appeared histologically similar to GFP-negative neigh-
boring crypts, containing markers of differentiated enterocytes
(Krt20 and Villin) and Goblet cells (Muc2 and Alcian blue) (Fig-
ure 4B, Figure S4).1544 Cell 161, 1539–1552, June 18, 2015 ª2015 Elsevier Inc.Apc-restored cells retained within re-
gressed tumors maintained the potential
for tumor growth and 10 weeks following
re-silencing of Apc, regressed polyps had
regrown to their original size (Figure 4C).
We repeated the cycle, this time main-
taining the animals off dox for 15 weeks,
and again all tumors showed regression
and subsequent regrowth at their original
sites (Figure 4C). Thus, Apc restoration in
colorectal polyps not only triggers differ-
entiation, but also restores normal ho-
meostasis in crypt based columnar cells,
even after multiple rounds of tumorigenic
growth and regression.
Reacquisition of Tissue
Homeostasis Is Cell Intrinsic
The in vivo experiments described
above provide a clear demonstrationthat Apc restored cells can re-establish normal behavior; how-
ever, closely following cell fate and differentiation capacity
longitudinally in a complex tissue is challenging. Ex vivo intes-
tinal crypt culture (Sato et al., 2009) provides a means to
directly interrogate cellular response to Apc in the absence of
a complex microenvironment. To ask whether Apc-restored
cells could reestablish the balance of self-renewal and multi-
lineage differentiation without cues from surrounding normal
tissue, we derived small intestinal crypt cultures from shApc
mice and examined their behavior following the addition and
withdrawal of dox. Consistent with studies using Apc mutant
Figure 4. Apc Restorations Re-establishes
Crypt Homeostasis
(A) Schematic representation of GFP relabeling
experiment. 4OHT treated mice that had been on
dox for 20 weeks (green bars) were removed from
dox treatment for 2 weeks (gray bar) to promote
Apc-driven tumor regression, then refed dox food
for 2 days to induce GFP expression. As a control,
naive shApc/Lgr5 mice were treated with 4OHT,
and then fed dox food for 2 days to indicate the
outcome of Apc shRNA induction for 2 days.
(B) Immunofluorescent (Krt20/GFP, Muc2/GFP
and Ki67/Villin) stains showing naive shApc/Lgr5
mice treated with 4OHT/dox for 2 days (upper left),
and shRen/Lgr5 (left) and shApc/Lgr5 mice (right)
pulsed with dox for 2 days after 2 weeks of
dox withdrawal. Arrowheads highlight GFP-posi-
tive (green arrowhead) and GFP-negative (white
arrowhead) crypts present in the regressing polyp.
(C) Longitudinal colonoscopic images of a dox-
treated shApc/Lgr5 mouse withdrawn and re-
treated with dox twice to induce tumor regression
and regrowth, for times indicated.organoids (Sato et al., 2011; Dow et al., 2015), shRNA-medi-
ated gene silencing of Apc triggered a transition to hyperproli-
ferative ‘‘spheroids’’ (Figures 5A and 5B). Like shApc-driven
adenomas, spheroids showed a significant increase in prolifer-
ation, a block in differentiation (marked by loss of Krt20, Alk
Phos and Muc2-positive cells) and loss of crypt-like projections
containing Paneth cells (Figure 5A). Restoration of Apc expres-
sion in this setting (Figure 5B) induced a rapid phenotypic
reversion, and by 4 days following dox withdrawal greater
than 90% of the culture showed morphological evidence
of normal differentiation and a dramatic increase in Krt20
staining (Figures 5A and 5C). Apc-restored organoids could
be maintained indefinitely in culture (Figure S5) and contained
all differentiated cell types present in untreated (dox naive)
cultures, including alkaline phosphatase-positive enterocytes,Cell 161, 1539–155Muc2-positive Goblet cells, and showed
relocalization of Paneth cells to the base
of crypt-like projections (Figure 5A).
Thus, Apc re-expression engages a cell
intrinsic mechanism to restore tissue
homeostasis, such that once aberrantly
proliferating cells can return to normal
crypt architecture capable of self-re-
newal and differentiation.
Kras and p53 Mutant CRCs Remain
Dependent on Apc Disruption
Although the response to Apc restora-
tion in polyps was dramatic, these le-
sions are benign and may not recapitu-
late the response of malignant CRCs to
Wnt pathway agonists. As adenomas
develop into carcinomas they acquire
additional genetic lesions, often acti-
vating mutations in KRAS (43% of hu-man CRC) or disruption of TP53 (54%) (Figure 6A), that could
modify the response to Apc restoration. Consistent with
this notion, mutational activation of Kras or loss of p53 in
Wnt1-driven mammary tumors is sufficient to bypass the
requirement for sustained Wnt activation in tumor maintenance,
leading to eventual relapse upon oncogene withdrawal (Debies
et al., 2008; Jang et al., 2006). Thus, we asked whether activa-
tion of Kras or loss of p53 would drive disease progression and/
or render colon tumors insensitive to Apc-mediated tumor
suppression.
To test this, we crossed a conditional Kras mutant allele (LSL-
KrasG12D, hereafter KrasG12D) and a conditional null p53 allele
(Trp53fl/fl, hereafter p53fl/fl) to our shApc/Lgr5 mice (Jackson
et al., 2001; Marino et al., 2000). Consistent with previous
work (Haigis et al., 2008; Hung et al., 2010; Janssen et al.,2, June 18, 2015 ª2015 Elsevier Inc. 1545
Figure 5. Apc Restores Self-Renewal and Multi-Lineage Differentiation
(A) Brightfield, epifluorescent, and immunofluorescent images of shApc intestinal organoid cultures treated and withdrawn from dox (0.5 mg/ml) as indicated. GFP
signal (second row) shows induction of the TRE-regulated GFP-shRNA transgene. Panels below show the induction of markers of differentiation (Krt20, Alk Phos
and Muc2) and localization of proliferative cells (EdU) and Paneth cells (lysozyme) at the base of crypts following Apc restoration (or in No Dox controls). Scale
bars, 50 mm.High-magnification images ofMuc2-positive cells in the villus-like domain and lysozyme-positive cells in the crypt are shown on the lower right. Scale
bars, 10 mm.
(B) Western blot of whole cell lysates from shRen and shApc intestinal organoid cultures following dox treatment and withdrawal at time points indicated.
(C) Graph represents the percentage (%) of undifferentiated spheroids (green) and differentiated, crypt-containing organoids (blue) in dox-treated and dox-
withdrawn shRen and shApc cultures.2006; Onuma et al., 2013), mutation of Kras (G12D) strongly
synergized with Apc suppression to promote rapid and wide-
spread tumor growth in both the small and large intestine of
shApc /KrasG12D/Lgr5 mice (Figure 6B, data not shown),
reducingmedian survival to 63 days (n = 15) (Figure 6D). Tumors
were highly proliferative and showed no evidence of differenti-
ation or cell death (Figure 6C). Similar to shApc/Lgr5 animals,
lesions were most apparent in the duodenum and colon,
although they were also observed in more distal regions of the1546 Cell 161, 1539–1552, June 18, 2015 ª2015 Elsevier Inc.small intestine (data not shown). Histologically the tumors
were composed of low-grade and high-grade tubular ade-
nomas, and intramucosal adenocarcinoma that sometimes
showed local invasion into the submucosa (Figure 6E, Fig-
ure S6A). Additional loss of p53 in shApc /KrasG12D/p53fl/fl/
Lgr5 mice did not significantly alter median survival (59 days,
n = 5) but drove more widespread features of intramucosal
adenocarcinoma (Figure 6E). Accordingly, while shApc organo-
ids formed benign sphere-like structures that did not progress
Figure 6. Kras and p53 Mutations Drive Disease Progression in shApc Tumors
(A) Oncoprint map representing frequency of gene loss (blue bars), mutation (green) and amplification (red) in TCGA analysis of humanCRC (www.cbioportal.org).
(B) Endoscopic images from shRen/Kras/Lgr5 and shApc/Kras/Lgr5 mice, 1 year and 6 weeks post-4OHT, respectively.
(C) Immunohistochemical (H&E) and immunofluorescent (Ki67, Krt20 and Cleaved-Caspase 3) stains from shRen/Kras, shApc/Kras, shRen/Kras/p53fl/fl and
shApc/Kras/p53fl/fl colons following dox treatment for 6 weeks (shApc mice) or 20 weeks (shRen mice). Arrows indicate regions of hyperproliferation driven by
KrasG12D, as previously described (Haigis et al., 2008).
(D) Kaplan-Meier plot showing survival of dox-treated shApc (dotted green line, also represented in Figure 2D), shApc/Kras/Lgr5 (purple line) and shApc/Kras/
p53fl/fl/Lgr5 (orange line), following 4OHT treatment at 5–6 weeks of age.
(E) Blind-scored histological analysis of intestinal sections from shApc/Lgr5, shApc/Kras/Lgr5 and shApc/Kras/p53fl/fl/Lgr5 mice, as indicated. Animals were
scored based on most advanced disease evident in an H&E section through the entire intestine.
(F) H&E stains section of tissue obtained sub-cutaneous transplanted shApc and shApc/Kras organoids/spheroids, 7 weeks following transplant.
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as sub-cutaneous transplants, shApc/KrasG12D organoids pro-
duced lesions that resembled adenocarcinomas, showing
nuclear atypia, loss of epithelial polarity, and a dramatic recruit-
ment of host stromal cells (Figure 6F, Figures S6B and S6C).
Kras mutation induced further upregulation in some key Wnt
targets, relative to shApc/Lgr5 tumors (Figure S7A), including
Myc, perhaps in part accounting for the enhanced tumor
growth.
Despite the dramatic acceleration of tumor initiation and pro-
gression in KrasG12D and KrasG12D/p53 mutant CRCs, restora-
tion of Apc still induced rapid and sustained tumor regression
(Figure 7A). Indeed, even in the context of these potent onco-
genic insults, we have not observed any relapse for over
15 weeks (n = 5 [Kras], n = 3 [Kras/p53]) (Figure S7A), with the
exception of small regions of hyperproliferation andmicroadeno-
mas also seen in shRen control animals that were presumably
due to Kras and/or p53 alteration (Figure 6, Figure S7B, arrows).
Tumor cells showed rapid cell-cycle arrest and differentiation,
identical to the response observed in shApc/Lgr5 adenomas
(Figure 7B, Figure S7B) and elevatedWnt target genes, including
those further upregulated followingKrasmutation (i.e., cMyc), re-
turned to baseline levels only 4 days following dox withdrawal
(Figure S7C).
As described for shApc/Lgr5-driven adenomas, we noted
areas of shApc /KrasG12D/Lgr5 regressed tumors (D14 off dox)
that showed ribbons of GFP-positive crypts following re-labeling
(Figure S7D). Re-labeled crypts contained differentiated entero-
cytes (Krt20 and Villin) and Goblet cells (Muc2) and showed pro-
liferation restricted to the base of the crypt, indicating that even
in the presence of a Kras mutation, Apc-restored cells can re-
establish normal tissue behavior. Similarly, Apc restoration in
KrasG12D andKrasG12D/p53/mutant spheroids induced a rapid
reversion to normal organoid structures, containing proliferative
crypt-like domains, and a differentiated central lumen (Figure 7C,
Figure S7E). Detailed staining revealed functional enterocytes
(Alk Phos) and Goblet cells (Muc2), as well as relocalization of
Paneth cells (lysozyme) to the base of crypts (Figure 7C). Apc
restored KrasG12D mutant organoids could be maintained indef-
initely in culture following Apc re-expression, implying they re-
tained long-term self renewal and differentiation capability
(Figure S5).
In addition to differentiation within the tumor mass, we iden-
tified regions of sub-mucosal invasion in Apc-restored animals
that showed strong expression of Krt20 (Figure 7D), implying
the differentiation response induced by Apc is maintained
even when cells have migrated beyond the borders of the
primary tumor. Consistent with this notion, subcutaneously
transplanted shApc/KrasG12D organoids showed sustained
regression in response to Apc restoration, forming sheets of
differentiated, monolayered epithelium (Figures S6B and
S6D). Together, these data show that mutational activation of
Kras and loss of p53 can drive CRC progression in Apc-
depleted intestinal epithelium but that the resulting carcinomas
remain strictly dependent on Apc disruption for sustained
tumor growth. Remarkably, even in the presence of potent
oncogenic mutations, cells within these tumors can re-establish
the homeostatic balance of self-renewal and differentiation in
response to endogenous Apc protein.1548 Cell 161, 1539–1552, June 18, 2015 ª2015 Elsevier Inc.DISCUSSION
The major genetic events that contribute to CRC have been
clearly delineated over the past 20 years, and more recently
elaborated using large-scale sequencing approaches. The high
percentage of APC loss-of-function mutations in CRC (80%–
90%) and their identification and functional characterization in
early, pre-malignant disease has supported the notion that this
is the initiating and driving event in tumor progression. However,
experimentally, the requirement for APC loss in tumor mainte-
nance has been challenging to address because restoring
normal gene function in tumors, without ectopic overexpression,
is difficult. To circumvent this technical challenge we used a
tissue-specific and mosaic shRNA-based transgenic model of
Apc loss that accurately recapitulates the histological and
molecular features of human CRC. This model revealed that
Apc loss is strictly required for disease maintenance, even in
the context of additional CRC-associated oncogenic insults
that drive progression to invasive cancer.
The vast majority of Apc-based CRC model systems gener-
ated to date develop tumors primarily in small intestine (Zeineldin
and Neufeld, 2013), or require the use of specific Cre strains to
effectively restrict disease development to the large intestine (Hi-
noi et al., 2007; Robanus-Maandag et al., 2010). Thus, due to
their bias toward the development of small intestinal disease,
these mouse models have been considered inadequate surro-
gates of human CRC. In contrast, the shRNA-driven, mosaic
model described here develops adenomas in both the duo-
denum and colon, consistent with common sites of polyp devel-
opment in FAP patients (Sarre et al., 1987). The reason behind
this difference remains unclear but may reflect differences in
the mechanism of Apc disruption and/or the level of Wnt
signaling induction. In agreement, analysis of human CRCs re-
veals selection for particular types of alterations inWNT pathway
modulators in different regions of the colon (Albuquerque et al.,
2010; Christie et al., 2013), while detailed comparisons between
the mouse and human intestine show distinct differences in the
expression of Wnt pathway genes (Leedham et al., 2013). Alter-
natively, the mouse-human differences in previous models may
be due to species-specific changes in stem cell behavior (Tom-
asetti and Vogelstein, 2015). However, differences in stem cell
behavior alone cannot account for the regional bias of Apc-
driven intestinal tumors because simply changing the mode of
Apc disruption (Apcfl/fl versus shApc) causes a ‘‘humanization’’
of tumor distribution (Figure 2E). Importantly, shApc-driven ade-
nomas show both the histological and molecular characteristics
of familial and sporadic APC mutant human adenomas and
CRCs. In addition to increasing its human relevance, the pres-
ence of colorectal tumorigenesis in the shApc model enables
longitudinal colonoscopic imaging as a powerful means to study
the initiation and progression of mammalian colorectal cancers.
The tumor response to the restoration of endogenous Apc pro-
tein was rapid and striking. Within days of dox withdrawal, tumor
cells suppressed Wnt target gene expression, ceased prolifera-
tion, and showed signs of intestinal differentiation. In fact, the
phenotypic response to Apc restoration was measurable days
before full Apc restoration was established (Figure 1D), implying
that only a very small amount of Apc is sufficient for tumor
Figure 7. Apc Restoration Induces Sustained Regression of Colorectal Adenocarcinoma
(A) Longitudinal colonoscopic images of dox-treated shApc/Kras and shApc/Kras/p53fl/fl mice, as indicated, and following 1, 3 and 6 weeks of dox withdrawal.
(B) Immunohistochemical (H&E) and immunofluorescent stains for Ki67 and Krt20 in shApc/Kras colon tumors, ONDox (left) or 4 days and 10weeks following dox
withdrawal. Scale bars, 100 mm.
(C) Immunofluorescent images of shApc/Kras intestinal organoid cultures (ON Dox and D4 OFF dox, as indicated) showing markers of proliferation (EdU), dif-
ferentiation (Krt20, Alk Phos and Muc2) and crypt integrity (Lysozyme). Scale bars, 50 mm. High-magnification images of Muc2 and lysozyme staining in Apc-
restored/KrasG12D organoids are shown below; scale bars, 10 mm.
(D) Immunohistochemical (H&E) and immunofluorescent stains (GFP/Krt20) of an invasive lesion in an shApc/KrasG12D/Lgr5 tumor where Apc was restored
14 days before pulsing with dox for 2 days to relabel GFP-positive cells prior to sacrifice.suppression. These data also support our earlier observations
that potent Apc silencing is critical to induce adenomas in
mice. Previous work has inferred the importance of sustainedAPC disruption and/or Wnt activity in maintenance of CRCs,
though these studies have largely relied on overexpression of
APC that induces changes in adhesion, migration, exosomeCell 161, 1539–1552, June 18, 2015 ª2015 Elsevier Inc. 1549
secretion, and/or trigger apoptosis, depending on the cell line
used and level of APC expression enforced (Faux et al., 2004;
Groden et al., 1995; Lim et al., 2012; Morin et al., 1996). In
some contexts, full-length APC re-expression inducesmolecular
and cell morphological changes reminiscent of terminal differen-
tiation (Faux et al., 2004) and this parallels observations that
RNAi-mediated b-catenin silencing can induce markers of differ-
entiation in certain human CRC cell lines (Scholer-Dahirel et al.,
2011). However, loss of b-catenin also drives ectopic differenti-
ation of normal intestinal epithelium (Fevr et al., 2007), suggest-
ing that completely blocking Wnt signaling would likely be
severely toxic to normal intestine. By contrast, our data show
that re-establishing normal control of this pathway through
endogenous Apc restoration is sufficient to induce rapid and
sustained tumor regression without deleterious effect on normal
crypt function.
Previous work using conditional transgenes has helped estab-
lish the concept of ‘‘oncogene addiction,’’ whereby tumors un-
dergo sustained regression following withdrawal of the driving
genetic event (Bellovin et al., 2013). In particular, disruption of
theMYC oncogene, a key factor supporting Apc-driven intestinal
disease (Sansom et al., 2007), can induce tumor regression via
multiple mechanisms: apoptosis, senescence and/or terminal
differentiation, depending on cellular context (Felsher, 2008). In
one example,Myc withdrawal leads to differentiation of hepato-
cellular carcinoma, and while tumor cells are retained in the
tissue, they lie dormant until Myc is re-induced (Shachaf et al.,
2004). In our model, at least some Apc-restored tumor cells
were capable of reverting to functional intestinal units, com-
posed of proliferative crypt bases and differentiated enterocytes
and Goblet cells. Remarkably, while reverted crypts maintain a
high proliferative rate, self-renewal capability and a predisposi-
tion for tumorigenesis, we observed no relapse of disease in
mice following dox withdrawal over more than 30 weeks.
Importantly, restoration of normal Wnt pathway regulation
by Apc induced disease regression and reestablished tissue
homeostasis even in tumors carrying KrasG12D and Trp53 muta-
tions. This observation stands in stark contrast to results obtained
using conditional Wnt- or Myc-driven mammary tumor models,
which showed that Kras or p53 mutations can relieve Wnt onco-
gene dependence (Debies et al., 2008; Jang et al., 2006). Indeed,
inmany tumorcontextsKrasandTrp53alterationsaresufficient to
initiate and sustain malignant disease (Hingorani et al., 2005;
Jackson et al., 2005). For example, in lung, Kras or Braf mutation
drivesdisease initiation,whilep53andWntalterationsenablepro-
gression (Feldser et al., 2010; Juan et al., 2014), whereas in colon,
our data suggest that Apc/Wnt deregulation is the master cancer
driver, while Kras and p53 play an important but supporting role.
What regulates this remarkable tissue-specific oncogene depen-
dence is not clear, butperhaps reflects the lineage-based require-
ment for highWnt activity in normal colonic tissue that is retained
as cells transform. Of course, while our data suggest that com-
bined Kras and p53 mutations are not sufficient to alleviate the
dependence on Wnt signaling, it is possible that other lesions or
specific environmental signals could confer such independence.
Regardless, the observation that Apc-restored tumor cells are
capable of multi-lineage differentiation is reminiscent of prior
work showing that nuclei derived from murine melanoma cells1550 Cell 161, 1539–1552, June 18, 2015 ª2015 Elsevier Inc.can be reprogrammed in wild-type oocytes, and in rare
instances, produce viable mice (Hochedlinger et al., 2004). To
our knowledge, our results provide the first demonstration
that neoplastic cells can reacquire their ability to balance self-
renewal and terminal differentiation upon re-establishing control
of a single tumor-suppressor pathway.
Our findings have important implications for the clinical utility
of strategies targeting theWnt pathway, particularly those aimed
at re-engaging the endogenous tumor suppression mecha-
nisms. First, although it is currently impractical to directly restore
wild-type APC function to CRCs, our results imply that small
molecules that aimed at modulating, but not blocking, the Wnt
pathway, might achieve similar effects. In this regard, the recent
development of small molecule Tankyrase (Tnk) inhibitors, which
modulate Wnt activity by regulating the activity of the b-catenin
destruction complex, represent a positive step in this direction
(Huang et al., 2009; Waaler et al., 2011). Second, we note that
the induction of differentiation upon Apc restoration is extremely
rapid, and occurswell before full Apc expression is restored. This
observation implies that only partial inhibition of hyperactive Wnt
signaling will be required for potent anti-tumor effects, while
sparing surrounding normal tissue. Third, our data suggest that
strategies to mimic Apc reactivation will drive the conversion of
some tumor cells to long-lived ‘‘normal’’ proliferative crypts
and thus require sustained suppression of the pathway to pre-
vent relapse. Still, given the high level of genomic instability
associated with CRC, it is difficult to imagine many tumor cells
reintegrating into normal tissue and, indeed, our lineage tracing
studies suggest that most tumor cells are eliminated upon differ-
entiation. Further work will be critical to determine whether Wnt
inhibition (or similar approaches) would provide long-term thera-
peutic value in the clinic, but it is clear that Apc disruption plays a
central role in driving and maintaining tumorigenesis, and that
CRCs carrying other potent oncogenic drivers likely remain
exquisitely sensitive to APC-mediated tumor suppression.
EXPERIMENTAL PROCEDURES
Animals
Animalsweremaintained on amixedC57B6/129 background unless otherwise
stated. Production of mice and all treatments described were approved by the
Institutional Animal Care and Use Committee (IACUC) at Memorial Sloan Ket-
tering Cancer Center (NY), under protocol number 11-06-012. Doxycycline
was administered via food pellets (625 mg/kg) (Harlan Teklad). 4-hydroxyta-
moxifen (4OHT, Sigma Aldrich, 70% Z-isomer) was delivered by a single intra-
peritoneal injection (0.5 mg/mouse) at 5–6 weeks of age. For DNA labeling
experiments, animals were injected with 1mg BrdU 2 hr prior to tissue harvest.
Immunohistochemistry and Immunofluorescence
Full staining and antibody detail provided as Supplemental Information. Briefly,
4% paraformaldehyde-fixed paraffin sections were rehydrated, unmasked,
and blocked in TBS / 0.1% Triton X-100 containing 1% BSA. Primary
antibodies were incubated at 4C overnight in blocking buffer. For immuno-
histochemistry, sections were incubated with anti-rabbit ImmPRESS HRP-
conjugated secondary antibodies (Vector Laboratories, #MP7401) and chro-
magen development performed using ImmPact DAB (Vector Laboratories,
#SK4105). Stained slides were counterstained with Harris’ hematoxylin. For
immunofluorescent stains, secondary antibodies were applied in TBS for
1 hr at room temp and sections counterstained with DAPI. In situ hybridization
for Olfm4 and Lgr5 were performed essentially as previously described (Gre-
gorieff et al., 2005) (van der Flier et al., 2009).
Isolation, Culture, and Staining of Small Intestinal and Colon
Organoids
Full detail for isolation and maintenance of organoids provided as Supple-
mental Information. Briefly, the intestine was removed, flushed, cut into
5 mm pieces and placed into 10 ml cold 5 mM EDTA-PBS and vigorously re-
suspended using a 10 ml pipette. After multiple washes, the supernatant was
aspirated and crypt-containing fractionwas collected twice following repeated
trituration. Crypts were filtered through 100 mm and 70 mm filters, collected by
centrifugation, resuspended in basal media and mixed 1:10 with Matrigel (BD,
354230). Growthmedia was changed on organoids every 2 days and theywere
passaged by mechanical disruption every 5–7 days. For subcutaneous trans-
plantation experiments, organoids were harvested and mechanically disrup-
ted as usual and then resuspended in 100 ml of 100% Matrigel, and then
injected into the flank of nude Foxn1nu mice. A sample of the resuspended
fragments were plated, allowed to reform organoid spheres over 24 hr, and
then counted to determine the total number of viable organoids transplanted.
On average, 40–60 ‘‘organoid forming units’’ were transplanted per injection.
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